Endo Withdraws Opana Painkiller From Market at FDA’s Request Post author:Sam Post published:July 6, 2017 Post category:Drug Industry Daily Endo will withdraw Opana ER from the market, following an FDA request in June. Source: Drug Industry Daily You Might Also Like FDA Unveils Draft Guidances on Innovative Trial Design September 28, 2018 Patient Groups Challenge CVS Plan to Deny Coverage Based on ICER Cost-Effectiveness September 17, 2018 FTC Strikes Deal on Pay-for-Delay Suit with Endo, Refiles Case Against Allergan January 23, 2017
Patient Groups Challenge CVS Plan to Deny Coverage Based on ICER Cost-Effectiveness September 17, 2018